GSK announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2023-24 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration FDA . GSK expects to distribute over 40M doses of its influenza vaccine to the US market. Both FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT will be available in a 0.5mL, single-dose, pre-filled syringe, and are indicated for patients six months and older. CDC recommends an annual flu vaccination for anyone aged six months and older who does not have contraindications.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GSK:
- BrainStorm appoints Bob Dagher as Chief Development Officer
- GSK says Bellus deal to be adjusted earnings accretive from 2027
- GSK receives FDA Fast Track designation for investigational gonorrhea vaccine
- GSK Pharma call volume above normal and directionally bullish
- GSK Rises after Reaching Settlement of Zantac Litigation